Neonatal Group B Streptococcal Septicemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for neonatal group b streptococcal septicemia. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
5
Active US patents
39/100
Avg vulnerability
—
Annual revenue covered

Originators in Neonatal Group B Streptococcal Septicemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

ANI Pharmaceuticals 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating neonatal group b streptococcal septicemia. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vancocin
vancomycin
 ANI Pharmaceuticals 5 39 — 2035-11-06

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11517609 Vancocin method of use 53 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
10849956 Vancocin formulation 25 2035-11-06
11000567 Vancocin formulation 25 2035-11-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10849956 Vancocin formulation 25 2035-11-06
11000567 Vancocin formulation 25 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
11517609 Vancocin method of use 53 2035-11-06

Related